Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Buy, Sell, or Hold: MAKO Surgical Corp. (MAKO)

When considering any stock for your portfolio, don’t be swayed by just the positives. Examine its pros and cons, and decide whether it’s possible upside outweighs its risks. Let’s take a look at MAKO Surgical Corp. (NASDAQ:MAKO) today, and see why you might want to buy, sell, or hold it.

Founded in 2004, based in Florida, and with a recent market capitalization of $480 million, MAKO is in the business of making medical devices — specifically, RIO Surgical robotic equipment and orthopedic implants. Its main offerings involve partial-knee arthroplasties and total hip replacements.

MAKO Surgical Corp. (NASDAQ:MAKO)

MAKO’s business arena is one big draw, thanks in part to our world’s growing and aging population. (Our obesity problem helps as well, as obesity can accelerate knee and hip degeneration.) According to my colleague Brenton Flynn, knee and hip procedures have been growing faster than the overall population, which bodes well.

The company’s revenue has been growing steadily, but its net income has remained negative. On the plus side, though, the losses have represented a shrinking portion of revenue. And while recently reported fourth-quarter earnings disappointed many investors, they were in line with company projections and do reflect continued growth and market acceptance. In 2012, the number of RIO procedures completed rose 29% over year-earlier levels.

Another plus is quality, as the RIO systems offer below-average failure rates.

One strike against the company is that its current offerings remain a bit limited in scope, addressing just partial knee replacements, for example, and not total replacements. The company’s performance in 2012 is also not auspicious, as it underperformed sales expectations and saw its stock plunge some 49%. (The stock soared more than 60% in 2009 and 2011, and more than 30% in 2010. These numbers also point to another drawback for some: volatility. If you can’t handle wide swings, steer clear.)

The stock’s valuation doesn’t reflect a screaming buy. Due to negative earnings, there’s no P/E ratio, and the recent price-to-sales ratio of 4.5 — while below the company’s five-year average of 15.3 — is well above the S&P 500’s 1.4 and the industry’s 2.1.

Dilution is another concern, as MAKO’s share count has been inching up. That’s not necessarily a dealbreaker, as funds generated from share issuances can help further growth. But adding shares does reduce the stake in the company claimed by the earlier shares.

MAKO has powerful competition, too, or potential competition, such as from Intuitive Surgical, Inc. (NASDAQ:ISRG) , which has a market value nearly 50 times greater than MAKO and has been posting strong double-digit growth in both revenue and earnings in recent years, with more and more hospitals buying its million-dollar daVinci machines. Right now, Intuitive’s business and MAKO’s don’t really cross paths.

An even bigger competitor, which is involved some of the same work as MAKO, is Johnson & Johnson (NYSE:JNJ) , which has a unit focused on orthopedic devices that generates more than $6 billion in revenue annually — in addition to other medical device businesses. Stryker Corporation (NYSE:SYK) and Zimmer Holdings, Inc. (NYSE:ZMH) are also working in orthopedic devices. Zimmer recently received the FDA’s blessing for a new guidance system for knee replacement procedures. Meanwhile, there’s a new competitor on the block — Blue Belt Technologies, with an FDA-approved orthopedic robotic surgical system.

Finally, there’s the new 2.3% tax on medical devices that companies such as MAKO will be required to pay. And as my colleague Dan Carroll has pointed out, it will hit unprofitable companies such as MAKO hard, as they won’t be able to pay it out of earnings.

Hold (off)
Given the reasons to buy or sell MAKO Surgical, it’s not unreasonable to decide to just hold off on it. You might want to wait for it to be offering machines that perform a wider range of procedures, or for its net losses to turn into net gains, ideally for a string of quarters.

You might also check out some other interesting related companies, to see if they seem like better bargains than MAKO. Perhaps take a look at Accuray Incorporated (NASDAQ:ARAY) , which specializes in radiosurgery and radiotherapy. Its stock is down some 42% over the past year, leading some to see it as bargain-priced now, with a recent price-to-sales ratio below 1. But it recently projected declining revenue due to manufacturing and supply issues. It’s worth learning more before jumping in.

The verdict
I’m actually a shareholder in MAKO already, though I’m underwater on it. It does seem potentially promising to me, but it’s far from low-risk. Everyone’s investment calculations are different, though. Do your own digging and see what you think. The company may perform spectacularly in the coming years, but remember that there are plenty of compelling stocks out there.

The article Buy, Sell, or Hold: MAKO Surgical originally appeared on and is written by Selena Maranjian.

Longtime Fool contributor Selena Maranjian, whom you can follow on Twitter, owns shares of Johnson & Johnson, MAKO Surgical, and Intuitive Surgical. The Motley Fool recommends Intuitive Surgical, Johnson & Johnson, and MAKO Surgical. The Motley Fool owns shares of Intuitive Surgical, Johnson & Johnson, and Zimmer Holdings.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.